Related Experiment Video

Updated: Feb 12, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.6K

Prophylactic and early targeted treatment of patent ductus arteriosus

Jonathan P Wyllie1, Samir Gupta2

  • 1Department of Neonatology, The James Cook University Hospital, Middlesbrough, UK; Durham University, Stockton-on-Tees, UK.

Seminars in Fetal & Neonatal Medicine
|March 25, 2018
PubMed

Insights

Treating a patent ductus arteriosus (PDA) in preterm infants is debated. This article reviews approaches to identify infants most likely to benefit from PDA treatment, focusing on evidence-based care.

Area of Science:

  • Neonatal medicine
  • Pediatric cardiology
  • Clinical research

Background:

  • Patent ductus arteriosus (PDA) is common in preterm infants.
  • Traditional PDA treatment is being re-evaluated due to conservative approach successes.
  • Evidence for long-term benefits of PDA treatment is limited.

Purpose of the Study:

  • To assess treatment strategies for hemodynamically significant PDA in very preterm infants.
  • To identify infants who would most benefit from PDA intervention.
  • To address the evolving clinical practice regarding PDA management.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Analysis of factors influencing PDA hemodynamics and outcomes.
  • Discussion of diagnostic and therapeutic approaches.

Main Results:

  • Hemodynamic significance is a key factor in determining the need for intervention.
  • Conservative management can be successful in select cases.
  • Identifying infants likely to benefit requires careful assessment of individual factors.

Conclusions:

  • A nuanced approach is needed for PDA treatment in preterm infants.
  • Treatment decisions should be individualized based on hemodynamic status and potential benefits.
  • Further research is needed to clarify long-term outcomes of different management strategies.

Keywords:
Early targeted treatmentIbuprofenIndomethacinPatent ductus arteriosusPretermProphylactic treatment

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.3K
Closure of a Patent Foramen Ovale PFO: An Intervention Sequence10:52

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence

Published on: December 23, 2022

6.1K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
976
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K